Where Is the Off Ramp for Psychotropic Medications?

When I first started taking an antidepressant as a teenager, no one talked to me or my parents about how I might eventually stop. Instead, the conversation was entirely centered on finding and starting the right medication. Since then, my prescription list has quietly grown — fluoxetine (Prozac) replaced with escitalopram (Lexapro), then venlafaxine (Effexor), the dose creeping upward, and eventually the addition of aripiprazole (Abilify), an antipsychotic used as an adjunct for treatment-resistant depression. Now, at 40, 8 years into sobriety and decades of mental health care, I’m beginning to question why my medications have only increased, never decreased.

Why does psychiatric treatment rarely include an exit strategy? We have well-worn roadmaps for starting psychotropic medications, but the field is just starting to develop guidelines for stopping them — a conversation largely lacking the voices of people with lived experience. Worse, there is a stunning lack of evidence documenting the long-term effects of these medications, even as this is how they are increasingly being used in the real world.

This gap has hit close to home for me. After years of treatment, significant behavioral and life changes, and months of contemplation, I recently began working with my prescriber to reduce my medication. I’ve been slowly tapering my dose of venlafaxine for the last few months and have now returned to the dose I was originally prescribed. Despite my steely resolve, the process has been difficult — fluctuating moods, low motivation, headaches, and the dreaded “brain zaps” that I’ve come to recognize as withdrawal. Continuing toward eventual cessation seems daunting.

My experience is not unique; in fact, it’s strikingly common. National data show that the number of prescriptions for psychiatric medications has risen significantly, even as research on their long-term benefits and risks remains limited. Antidepressants are usually prescribed during acute periods of distress, yet in the U.S. the median user will stay on them for approximately 5 years and the majority (70%) will take them for more than 2 years. This is striking given that the evidence of effectiveness for antidepressants is generally derived from clinical trials ranging in length from 6-to-12 weeks.

In practice, treatment often defaults to continuation, not because it is always necessary, but because there are few established pathways for safely stopping. Unlike many other areas of medicine, there are few widely implemented or well-established standards for when and how to taper or discontinue psychiatric medications. Patients may feel reluctant to lead the charge lest they be characterized as difficult, lacking insight, or “non-compliant.”

For those who do consider stopping, the process is rarely straightforward. Many patients experience withdrawal symptoms, sometimes called “discontinuation syndrome.” In online patient communities, they report symptoms that can include anxiety, insomnia, and the “brain zaps” I’ve experienced. Research suggests that these withdrawal symptoms may be more common and longer-lasting than previously recognized.

These symptoms are often difficult to distinguish from relapse, creating a clinical gray area where both patients and providers may default to resuming medication. Without clear guidance, patients are often left to interpret withdrawal symptoms on their own — and to decide whether to continue, taper, or stop medications without adequate support.

While emerging guidelines are a start, the fact remains that there is little formal training in deprescribing education for providers. Unlike other areas of medicine, where medication reviews and step-down plans are more routine, mental health care rarely builds in regular reassessment with a goal of deprescribing. More tools to support equitable shared decision-making are needed. The field has invested decades in developing and prescribing these medications; it’s past time to invest similarly in understanding how to use them safely over the long term, and how to stop them when appropriate.

This inertia has real consequences. Common and serious risks of psychotropic medications include weight gain, metabolic syndrome, sedation or mental fogginess, and drug-induced movement disorders (e.g., tardive dyskinesia). Patients should not be subject to potential side effects longer than necessary, and especially not for medications for which the long-term health consequences are unknown.

Public discourse, including recent comments from HHS Secretary Robert F. Kennedy Jr. questioning antidepressant prescribing practices, has brought renewed attention to these concerns. But this conversation should not devolve into simplistic pro- or anti-medication narratives. Psychiatric medications help many people, including me. The real issue is whether patients and clinicians have the evidence, guidance, and support needed to make informed decisions about long-term use and safe discontinuation. Clinicians should build regular medication reviews into care, with explicit discussion of whether tapering is appropriate, and patients should be informed from the outset about the challenges of discontinuation.

To support this shift, we also need to invest in research on the long-term efficacy of psychotropic medications as well as their adverse effects and how to taper them safely. We cannot provide truly evidence-based care without robust data on how these medications are used — and discontinued — in the real world.

Starting medication should never be the only plan. An exit strategy should be part of the conversation from the very beginning.

Please enable JavaScript to view the comments powered by Disqus.